A prospective, open, randomized, comparative treatment trial was conducted to compare the therapeutic efficacy of the conventional four-drug combination (chloramphenicol, trimethoprimsulfamethoxazole, and doxycycline) with that of doxycycline alone in oral maintenance treatment of melioidosis. Adult Thai patients with culture-confirmed melioidosis were randomized to receive treatment with either regimen for a minimum of 12 weeks, usually following intravenous treatment of severe disease. The main outcome measure was culture-confirmed relapse. One hundred sixteen patients were enrolled; 109 had culture-confirmed melioidosis, and 87 were considered evaluable (43 had received doxycycline). Culture-confirmed relapse occurred in one patient randomized to the conventional regimen and in 11 (25.6%) randomized to the doxycycline regimen (P ‫؍‬ .009), and treatment failed for 8 (18.2%) versus 20 (46.5%), respectively (P ‫؍‬ .009). Adverse effects occurred in 26% of patients overall. Doxycycline alone cannot be recommended for a first-line regimen of oral maintenance treatment of melioidosis.
The current means of treatment of melioidosis are unsatisfactory [1] . Prolonged oral therapy is required to control the infection, whether it follows intravenous therapy for severe infection or is given alone for milder infection. The conventional maintenance treatment is with a four-drug combination regimen of chloramphenicol, trimethoprim-sulfamethoxazole (TMP-SMZ), and doxycycline.
With 8 weeks' treatment, almost a quarter of patients experience a relapse. Although administration of treatment for 20 weeks can reduce the relapse rate to ϳ10%, this is expensive and potentially toxic. Because of the large number of tablets required each day and the long duration of treatment, compliance is usually poor. Only one comparative trial of an alternative maintenance treatment for melioidosis has been reported; in this trial, investigators compared amoxicillin-clavulanic acid (co-amoxiclav) with the conventional four-drug combination [2] . Co-amoxiclav was better tolerated and could be administered to children and pregnant women, but it was considerably more expensive and when used in short courses (Ͻ12 weeks) was less effective. Ciprofloxacin has also been evaluated in an open trial but was associated with a 30% failure rate [3] .
Thus, although the four-drug-combination regimen carries a higher risk of serious toxicity and there is in vitro evidence of antagonism [4] between the component drugs, it remains the oral maintenance treatment of choice for melioidosis. Simple, effective, less-toxic alternative regimens are still needed. In vitro studies indicate that doxycycline is the most active of the available oral antibiotics [5] . It has been successfully used alone as maintenance treatment in Australia [6] , but no comparative trials have been reported. We therefore conducted a prospective, randomized comparison of doxycycline alone and the conventional four-drug combination in the oral maintenance treatment of melioidosis.
Patients and Methods
All adult patients (Ͼ14 years old) admitted to Sappasitprasong Hospital (Ubon Ratchathani, Thailand) who had cultureconfirmed melioidosis and satisfactorily completed intravenous therapy (with ceftazidime [120 mg/(kg ⅐ d)], imipenem [50 mg/(kg ⅐ d)], or co-amoxiclav [160 mg/(kg ⅐ d)]) were eligible for this study if they gave informed consent. Patients with mild localized disease who did not require intravenous treatment were also eligible. Patients were enrolled if they agreed to return for follow-up.
Patients were excluded from the trial if they were pregnant, had known allergies to one of the study drugs, or were infected with a strain of Burkholderia pseudomallei known to be resis-tant to one of the study drugs. B. pseudomallei was identified and susceptibility testing was performed as previously described [7] . The Ethical and Scientific Review Subcommittee of the Thailand Ministry of Public Health gave approval for this study, which followed the guidelines in the Declaration of Helsinki.
Study design. This was an open-label, randomized, comparative treatment trial of the conventional four-drug combination (chloramphenicol, TMP-SMZ, and doxycycline) vs. doxycycline alone, for patients requiring oral maintenance treatment of melioidosis. The study protocol is available on request. The study was designed to detect a difference in failure rates of 35% and 10% with 95% confidence and 80% power. The intention was to study ϳ100 patients (50 in each group).
The primary outcome measure was the number of cultureconfirmed relapses. Secondary outcome measures were incidence of clinical failure (defined as failure to improve during administration of therapy or development of new symptoms consistent with relapse, without culture confirmation), overall treatment failure (defined as either clinical failure or culturepositive relapse), and drug allergy or intolerance; mortality rate; and duration of treatment.
Treatment. Patients were randomized to receive treatment with the conventional combination or doxycycline alone. The combination consisted of chloramphenicol (ϳ40 mg/[kg ⅐ d] for the first 4 weeks only; usual adult dosage, 500 mg q6h), doxycycline (4 mg/[kg ⅐ d]; usual dosage, 100 mg q12h), and TMP-SMZ (ϳ8 and 40 mg/[kg ⅐ d], respectively; usual dose, 960 mg q12h). Doxycycline administered alone was at a dosage of 4 mg/(kg ⅐ d) (usual dosage, 100 mg q12h).
Randomization was in blocks of 10, and the allocations were put in sealed envelopes, which were opened only when the decision to start oral treatment had been made. All drugs were manufactured by the Government Pharmaceutical Organization of Thailand. There is considerable variation in the severity of melioidosis, and thus the treatment duration was not fixed. The intention was to give antibiotic therapy for a minimum of 12 weeks and an average of 20 weeks, but the maximum duration was to be decided by the attending clinician for each individual patient, according to clinical progress.
No other oral antibiotics were given. All patients were subsequently reviewed as outpatients by one of us (W. C.), at first monthly and thereafter at a frequency dependent on clinical progress.
Investigations. At each follow-up visit all previously positive cultures or laboratory tests for which results were abnormal were repeated as necessary. All patients were weighed and underwent a full clinical examination. Investigations such as chest radiography or abdominal ultrasonographic scanning (e.g., if patients had liver or splenic abscesses) were repeated as necessary.
Management of relapse or drug allergy. Relapses of infection were treated as in primary episodes, and patients were readmitted to the hospital for intravenous therapy if indicated. Milder cases were usually treated by switching from oral therapy to a co-amoxiclav regimen or, for patients randomized to doxycycline, to the four-drug conventional therapy. The four-drug regimen was used for subsequent oral maintenance treatment of confirmed relapses. Co-amoxiclav was substituted in cases of suspected drug allergy.
Antimicrobial susceptibility. Susceptibility to ceftazidime, imipenem, chloramphenicol, doxycycline, and co-amoxiclav was initially performed by disk diffusion for all isolates [7, 8] . Routine testing of TMP-SMZ was not performed, as the results are difficult to interpret (endpoints are very imprecise) [5] . MICs of doxycycline were determined [5, 8] for all primary isolates, and in cases of relapse, for primary and relapse isolates in parallel.
Statistical analysis. Normally distributed continuous data were compared with Student's t test. Data not conforming to a normal distribution were compared by means of the MannWhitney U test. Proportions were compared with use of the 2 test with Yates' correction. Survival rates were plotted by the Kaplan-Meier method and compared with the log-rank test. A Cox's proportional hazards regression model was constructed to examine the influence of covariates other than oral drug treatment upon outcome. All analyses were performed with use of the statistical computing package SPSS for Windows, version 7.5.1 (SPSS, Chicago).
Results
Patients were enrolled in the study between October 1994 and August 1997. The follow-up period in this report extends to September 1998. A total of 116 patients were enrolled, 58 into each treatment group. Study details are shown in tables 1 and 2. Seven patients were excluded from further analysis because they were not proved by culture to have melioidosis (although it was the presumed diagnosis). Four patients were withdrawn from the study before they left the hospital because they were not given treatment with the regimen to which they were randomized, and one patient was randomized incorrectly. Seventeen patients (8 in the four-drug treatment group) failed to return for follow-up. This left 87 patients (75%) who returned for at least one follow-up visit or for whom the final outcome was known. Analysis of the results was restricted to these 87 evaluable patients. Baseline characteristics. Patients in the two arms of the study were similar in terms of age, sex, and occupation (table  3) . Only one patient had not previously received intravenous antibiotics. Five patients had been treated previously for confirmed melioidosis (four were in the four-drug treatment group; P ϭ .2). The incidence of underlying diseases such as diabetes mellitus or chronic renal impairment was similar for the two groups. Of the 87 evaluable patients, 35 (40.2%) had positive blood cultures on admission to the hospital.
Overall, patients with confirmed melioidosis enrolled in the doxycycline treatment group were more likely to have positive blood cultures and disseminated disease. Most patients with melioidosis (n ϭ 103; 94.5%) had received either intravenous ceftazidime or imipenem as first-line therapy, and 78 had been enrolled in a comparative trial of these two agents for treatment of severe melioidosis. This trial will be reported separately. Five patients had received intravenous co-amoxiclav.
Patients randomized to receive doxycycline were also more likely to have received ceftazidime as first-line intravenous therapy, but similar numbers in each treatment group had received imipenem initially or had required a switch of intravenous therapy. Total duration of intravenous therapy prior to enrollment in the trial was similar for the two treatment groups (median, 15 days). Evaluable patients were followed up for a median time of 15 months (range, 0 -44 months; interquartile range, 6 -22 months).
Duration of treatment. Treatment durations are shown in table 2. Thirty-two (72.7%) of the evaluable patients in the conventional-treatment group, vs. 23 (53.5%) of those in the doxycycline group, completed at least 12 weeks of therapy with this regimen plus prior intravenous therapy (P ϭ .1). Four patients (9.1%) vs. 14 (31.8%), respectively, were switched to another regimen on clinical grounds (P ϭ .02). Among doxycycline-treated patients this change was primarily due to clinical failure. Similar numbers of patients in each treatment group completed at least 12 or 20 weeks (in total) of treatment. The median duration of treatment during the first regimen was 18 weeks (interquartile range, 8 -19 weeks) for conventional therapy and 12 weeks (interquartile range 4 -18 weeks) for doxycycline (P ϭ .03). When intravenous treatment was included, 27 (61.4%) vs. 18 (41.9%), respectively, completed 20 weeks of therapy (P ϭ .11).
Relapse. Twelve evaluable patients had culture-positive relapses of their infection. Culture-confirmed relapse occurred in only one patient randomized to receive conventional treatment and in 11 (25.6%) randomized to receive doxycycline alone (P ϭ .009). The patient in the conventional-treatment group who relapsed had taken the medication for only 4 days before stopping because of the development of a rash. Since he did not report the adverse effect and did not return for outpa- tient follow-up, he received no further study treatment. He relapsed 44 weeks after starting oral therapy and made a successful recovery following further intravenous treatment (with imipenem) and maintenance treatment with co-amoxiclav for 17 weeks. The 11 patients who relapsed after starting oral doxycycline relapsed at a median time of 20 weeks (range, 1-169 weeks; interquartile range, 6 -47 weeks) after being enrolled. They had received a median of 6 weeks of therapy with doxycycline (range, 1-19 weeks; interquartile range, 4 -17 weeks). Four of the doxycycline treatment group patients who relapsed had been switched to a second regimen (co-amoxiclav) on clinical grounds prior to relapse, and each of these patients had received at least 20 weeks' total treatment. Eight of the 11 patients had received at least 12 weeks' total therapy, and six patients had completed 20 weeks of treatment.
Three patients relapsed while receiving treatment with doxycycline. Four doxycycline treatment group patients died as a result of the relapse. A Kaplan-Meier plot showing relapse-free survival for each drug regimen is shown in figure 1 .
As more patients in the doxycycline treatment group were septicemic on admission to the hospital, a further analysis was conducted to examine the potential confounding effects that this and other cofactors might have on the incidence of relapse. A Cox's proportional hazards regression model was constructed (n ϭ 77) to examine the influence of age (categorized by quartiles/medians), sex, septicemia, oral and intravenous drug treatment, and duration of intravenous therapy (categorized as for age). In this model, the choice of oral drug regimen remained the only significant risk factor for relapse, independent of the other factors (P ϭ .022; hazard ratio, 12.0; 95% CI, 1.4 -100.8).
Among the 70 patients completing at least 12 weeks' total treatment (including those switched to a second regimen), 8 (22.9%) of 35 doxycycline recipients relapsed, vs. none of 35 conventional-treatment recipients (P ϭ .009); of the 54 patients completing at least 20 weeks' total treatment, 6 (23.1%) of 26 vs. none of 28, respectively, relapsed (P ϭ .024).
Of the 55 patients completing at least 12 weeks of treatment without having switched to a second regimen, 4 (17.4%) of 23 doxycycline recipients vs. none of 32 conventional-treatment recipients relapsed (P ϭ .054), while of the 45 patients completing at least 20 weeks of treatment without having switched, 3 of 18 (16.7%) vs. none of 27 relapsed (P ϭ .113).
Antimicrobial susceptibility. MICs of doxycycline against all primary isolates lay in the range of 0.5-4.0 mg/L; thus, they may be considered susceptible. MICs for all relapse isolates were within one twofold dilution of those for the primary isolates except in one case, in which the MIC rose from 2 mg/L to 16 mg/L. All primary isolates were susceptible to both chloramphenicol and co-amoxiclav, and there was no development of resistance to either of these two drugs in relapse isolates.
Treatment failure. Four patients (9.1%) in the conventional-treatment group vs. 14 (31.8%) in the doxycycline treatment group were switched to another oral regimen on clinical grounds (P ϭ .02); for 2 (4.5%) vs. 10 (23.3%), respectively, this switch was due to clinical failure of therapy (i.e., failure of condition to improve). Therapy for one patient in each treatment group was switched because of side effects. A further six patients (four in the conventional-treatment group) were considered clinically to have suffered relapses after finishing oral treatment (although this was not proven by culture).
Two patients (both doxycycline-treated) whose therapy was considered to be a clinical failure required readmission to the hospital for intravenous treatment. These two patients both subsequently had culture-confirmed relapses requiring further readmission for treatment. One patient in each treatment group died shortly after starting oral treatment and before leaving the hospital. Both cases were considered clinical failures. Thus, for seven (15.9%) in the conventional-treatment group vs. 13 (30.2%) in the doxycycline treatment group, the first oral treatment regimen was considered a clinical failure (P ϭ .18).
Overall treatment failure (clinical failure or culture-positive relapse) occurred for eight (18.2%) of the conventionally treated patients vs. 20 (46.5%) of the doxycycline-treated patients (P ϭ .009). A Kaplan-Meier plot of time without treatment failure is shown in figure 2 .
Retreatment results. Eleven patients (all with cultureconfirmed relapses) were readmitted to the hospital. Two of them were also admitted previously for intravenous treatment following clinical treatment failure (i.e., culture-negative presumed relapse), prior to the culture-confirmed episodes of relapse. Six patients were retreated with ceftazidime, two with co-amoxiclav, and three with imipenem. Four patients (33.3%) died of relapsed infection and seven survived to be discharged from the hospital. The four patients switched from the conventional-treatment group on clinical grounds all received co-amoxiclav subsequently. None have relapsed, although one received a total of 42 weeks of treatment. Seven of the 14 doxycycline recipients whose therapy was switched subsequently received coamoxiclav, 2 received a combination of TMP-SMZ and doxycycline, and 5 were treated with the full conventional regimen. Four have relapsed subsequently; all four had been switched to co-amoxiclav and had received therapy for a total duration of Ͼ20 weeks, with clinical improvement.
Mortality. Ten (9.2%) of the 109 patients with melioidosis enrolled in the trial are known to have died: 4 from the conventional-treatment group and 6 from the doxycycline group. This may be an underestimate of the true mortality, as a further 16 patients were lost to follow-up (including seven in the four-drug treatment group), and the outcome of their infections was unknown. One patient lost to follow-up was known to have died but no clinical information was available. Among patients in the doxycycline treatment group, four died following culture-confirmed relapses, one died before leaving the hospital (this was considered a clinical failure of doxycycline), and one died of presumed liver carcinoma. Among patients in the conventional-treatment group, one died before leaving the hospital, two died of unknown causes, and one died of cholangiocarcinoma.
Adverse effects. Adverse effects were common in both treatment groups of the study, affecting 23 (26.4%) of the 87 evaluable patients overall. There was a trend toward adverse effects being more common with the conventional regimen (31.8% of patients, vs. 20.9% with doxycycline; P ϭ .2). Common side effects included skin rashes and facial erythema. Seven patients (including four treated with the four-drug regimen) developed symptoms consistent with photosensitivity, i.e., facial or exposed-site skin rashes. One patient developed skin hyperpigmentation while taking the four drugs. Vomiting was a particular problem with the conventional regimen, affecting five patients (11.4%).
Only one patient receiving doxycycline reported persistent vomiting, but three others complained of nausea and abdominal discomfort. There were no serious adverse effects.
Discussion
Melioidosis is a serious infection with a high relapse rate [9] . Before the introduction of ceftazidime, the mortality associated with severe melioidosis treated with the four-drug combination of chloramphenicol, doxycycline, and TMP-SMZ was Ͼ70% [10] . However, these four drugs are still used in oral maintenance treatment, following the use of intravenous ceftazidime or as the sole means of therapy for uncomplicated melioidosis. The mortality and morbidity associated with relapses are similar to that seen in primary infections [9] .
Previous studies have shown that a total duration of treatment of 8 weeks is associated with relapse in almost onequarter of patients. Treatment for between 12 and 20 weeks reduced this rate to Ͻ10% [2] . Few trials of oral maintenance therapy have been conducted [2, 3, 11] . The best current regimens are with the oral conventional four-drug combination, which is relatively inexpensive but potentially toxic and associated with poor compliance, and co-amoxiclav, which is expensive and probably slightly inferior in terms of efficacy [2, 11] .
Fluoroquinolones are active in vitro but disappointing in vivo [3] . They have been associated with a failure rate of Ͼ30% despite up to 20 weeks of treatment. Simpler, less-toxic, effective regimens are required. New drugs are needed, but no suitable new agents have appeared in recent years. We are therefore left with older drugs and the necessity of optimizing their use.
This study demonstrates that doxycycline, used alone in maintenance treatment of melioidosis, is associated with unacceptably high relapse and clinical failure rates. Many of the patients (Ͼ30%) initially randomized to receive doxycycline were switched early in their course of treatment to an alternative regimen, but Ͼ25% of patients relapsed. This is despite the fact that similar numbers of doxycycline vs. conventionaltreatment recipients completed either 12 or 20 weeks of treatment in total (including those who were switched to a second regimen). Even among the patients completing 12 or 20 weeks' total treatment after starting therapy with doxycycline, the relapse rate was significantly higher than for patients treated with the conventional regimen.
The doxycycline MIC values for relapse isolates changed significantly in only one case, indicating that development of resistance to the single agent was not an important factor influencing relapse. The overall failure rate for doxycycline approaches 50%. This indicates that one or more of the other components of the conventional regimen contributes signifi- cantly to treatment outcome. The four drugs in the conventional treatment regimen are bacteriostatic and mutually antagonistic [4] . Doxycycline is the most active of the four drugs in terms of conventional MIC assessments, although endpoints with TMP-SMZ are notoriously difficult to determine [5] . The better therapeutic response with the conventional regimen could reflect differences in tissue penetration. It is possible that doxycycline does not adequately access resolving abscesses or sequestered intracellular viable organisms.
Despite the clear differences between the two regimens, there are some limitations to this study. A large number of patients were considered nonevaluable. This was an open, although randomized, trial. Compliance with both of the drug regimens and with follow-up was not good. Although compliance was not formally assessed, there was no evidence from patient-questioning that compliance with doxycycline (2 tablets per day) was worse than with the conventional four-drug regimen (usually 14 tablets or capsules per day). However, it is not surprising that adverse effects were more common in the conventional-treatment group.
The combination of large doses (a large number of tablets or capsules per dose) and a high incidence of side effects might be expected to contribute to poor compliance with the four-drug regimen, which is a major drawback. A cheap, effective singleagent regimen would be a considerable advance. We did not introduce any measures specific to this trial in order to optimize compliance with either regimen, so it is unlikely that compliance would be significantly worse outside of the trial setting. Doxycycline alone cannot be recommended for a first-line regimen. Further studies of other regimens are still required, particularly a comparative trial of the conventional four-drug regimen vs. combination doxycycline-TMP-SMZ (without chloramphenicol).
